Clinical Trials Directory

Trials / Conditions / IDH Mutation

IDH Mutation

8 registered clinical trials studyying IDH Mutation — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingPhase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangioca
NCT07260175
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPhase 2
RecruitingWindow of Opportunity Study of DSP-0390 in Gliomas
NCT06636162
Washington University School of MedicineEARLY_Phase 1
RecruitingAll-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
NCT05345002
Stephen Bagley, MD, MSCEPhase 2
WithdrawnSurgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
NCT05061251
University of Texas Southwestern Medical CenterEARLY_Phase 1
WithdrawnA Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neopla
NCT04955938
University of ChicagoPhase 1
RecruitingMetabolic Characterization of Space Occupying Lesions of the Brain
NCT04233788
Insel Gruppe AG, University Hospital Bern—
CompletedTalazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
NCT04740190
The University of Hong KongPhase 2
RecruitingStudy of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
NCT03991832
University Health Network, TorontoPhase 2